EU GMP Annex 22: what the draft AI annex asks of GMP manufacturers
By QLogix · Published · 4 min read
Draft Annex 22 is the first GMP annex written for AI. It allows static, deterministic models in critical GMP applications, keeps generative AI out of them, and asks for a defined intended use, independent test data and ongoing monitoring.
- Status in October 2026. No date of application has been set.
- Draft
- Close of the stakeholder consultation.
- 7 Oct 2025
- Model type the draft accepts in critical GMP applications.
- Static only
Key takeaways
- Annex 22 is a draft. The consultation ran from July to 7 October 2025, and no final text had been published when this article was last updated.
- The draft covers AI models used in critical GMP applications and limits them to static models with deterministic output.
- Generative AI and large language models are excluded from critical GMP applications. In non-critical uses the draft expects qualified people to review the output.
- The work it asks for is familiar validation work: a documented intended use, acceptance criteria set in advance, test data kept independent of training data, and monitoring in operation.
What is EU GMP Annex 22?
Annex 22, Artificial Intelligence, is a proposed new annex to EudraLex Volume 4, the EU's good manufacturing practice guidelines. The European Commission published it for consultation in July 2025 together with a revised Annex 11 (computerised systems) and a revised Chapter 4 (documentation). It was drafted jointly with PIC/S, so the same text is expected to reach PIC/S member authorities outside the EU.
It is the first GMP annex written specifically for AI. Annex 11 continues to cover computerised systems in general, and Annex 22 adds requirements for the model itself: how it is selected, trained, tested and kept under control.
Is Annex 22 in force?
No. The stakeholder consultation closed on 7 October 2025. When this article was last updated, the final text had not been published and no date of application had been set. Check the European Commission's consultation page listed under Sources for the current status before you plan against a date.
Draft or not, the direction is clear enough to act on. Inspectors already expect computerised systems to be validated for their intended use under Annex 11, and the draft shows how regulators intend to read that expectation for AI.
Which AI models does the draft allow in critical GMP applications?
The draft applies to AI models used in critical applications: those with a direct impact on patient safety, product quality or data integrity. For those applications it accepts only static models, meaning models that do not keep learning once they are in use, and only models with deterministic output, meaning the same input gives the same output.
- Allowed in critical applications: static machine learning models with deterministic output, for example a classifier trained once and then locked.
- Not to be used in critical applications: dynamic models that continue to learn in operation, and models with probabilistic output.
- Not to be used in critical applications: generative AI and large language models.
What draft Annex 22 allows, by model type and use
| Model type | Critical GMP application | Non-critical application |
|---|---|---|
| Static model, deterministic output | Allowed, under the annex's requirements | Allowed |
| Dynamic model that keeps learning in use | Not to be used | Outside the annex's scope |
| Model with probabilistic output | Not to be used | Outside the annex's scope |
| Generative AI, large language models | Not to be used | Allowed with qualified human review of the output |
What does the draft say about generative AI?
The draft states that generative AI and large language models should not be used in critical GMP applications. Where they are used in non-critical applications, it expects personnel with adequate qualification and training to be responsible for checking that the output is fit for its purpose, which is a human-in-the-loop arrangement.
That is the line most quality teams already draw. A language model can draft an investigation summary, propose a root cause hypothesis or flag a record for attention. A qualified person reviews the draft, decides, and signs. The decision and the accountability stay with that person.
What does a manufacturer have to do for a model in scope?
- Describe the intended use in full, including the inputs the model is expected to see and the limits of that range.
- Set acceptance criteria before testing, with performance at least as good as the process the model replaces.
- Keep test data independent of the data used for training and validation, and show that it represents the intended use.
- Show which features drive the model's output, and record a confidence score so that low-confidence results are flagged instead of acted on.
- Keep the model under change control and configuration control, monitor its performance in operation, and watch for input data drifting outside the range it was tested on.
- Where a person reviews the output, define that review in procedures and train the reviewers.
What should a quality team do now?
- List every place AI is used or planned in GMP activities, and mark each one critical or non-critical.
- For generative AI, write down what the tool does, what the reviewer checks, and where the reviewer's decision is recorded.
- For machine learning models in critical use, gather the intended use statement, the test data and the acceptance criteria, and identify the gaps against the draft.
- Read the revised Annex 11 alongside it. Its requirements for audit trails, supplier oversight and security apply to the systems that host these models.
Common questions
Does Annex 22 ban generative AI in pharmaceutical manufacturing?
No. The draft says generative AI and large language models should not be used in critical GMP applications, which are those with a direct impact on patient safety, product quality or data integrity. In non-critical applications they can be used with qualified people responsible for reviewing the output.
When does Annex 22 take effect?
No date has been set. The consultation closed on 7 October 2025 and the final text had not been published when this article was last updated in October 2026.
Does Annex 22 replace Annex 11?
No. Annex 22 adds requirements specific to AI models. Annex 11 continues to apply to the computerised systems those models run in, and a revised Annex 11 was published for consultation at the same time.
Sources
This article is general information for quality and regulatory professionals. It is not regulatory or legal advice. Check the source documents for their current status before acting on them.
More from the blog
- AI in quality · 12 October 2026FDA's seven-step credibility framework for AI, in plain termsFDA's draft guidance asks sponsors to show that an AI model is credible for a specific context of use. The effort scales with model risk: how much the model's output drives the decision, and how serious a wrong decision would be.
- Manufacturing science · 12 October 2026AI in drug manufacturing: where FDA stands and what to build forFDA has no final guidance written only for AI in drug manufacturing. It has a 2023 discussion paper naming five open areas and a 2025 draft framework that covers manufacturing models. Together they show what a process model has to prove.
- Medical devices · 12 October 2026AI-enabled medical devices: what FDA's list and guidance showFDA's public list counted 1,614 AI-enabled medical devices through June 2026, about three in four of them in radiology. Two documents shape how they are built and changed: the final guidance on predetermined change control plans and the draft guidance on lifecycle management.